Application
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)Application
Figure 2:Western blot analysis using SEC31A mAb against human SEC31A (AA: 429-571) recombinant protein. (Expected MW is 41.8 kDa)Application
Figure 3:Western blot analysis using SEC31A mAb against HEK293 (1) and SEC31A (AA: 429-571)-hIgGFc transfected HEK293 (2) cell lysate.Application
Figure 4:Immunohistochemical analysis of paraffin-embedded ovarian cancer tissues using SEC31A mouse mAb with DAB staining.| Product Name | SEC31A |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | ABP125; ABP130; HSPC275; HSPC334; SEC31L1 |
| Immunogen | Purified recombinant fragment of human SEC31A (AA: 429-571) expressed in E. Coli. |
| Clonality | Monoclonal |
|---|---|
| Host Species | Unknow |
| Tested Applications | WBIHCICC/IF |
| WB:1:250~1:1000 IHC:1:20~1:100 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | Human |
| Alternative Names | ABP125 ABP130 HSPC275 HSPC334 SEC31L1 |
|---|---|
| Molecular Weight(MW) | 133kDa |
| Entrez Gene | 22872 |
|---|
Application
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Application
Figure 2:Western blot analysis using SEC31A mAb against human SEC31A (AA: 429-571) recombinant protein. (Expected MW is 41.8 kDa)
Application
Figure 3:Western blot analysis using SEC31A mAb against HEK293 (1) and SEC31A (AA: 429-571)-hIgGFc transfected HEK293 (2) cell lysate.
Application
Figure 4:Immunohistochemical analysis of paraffin-embedded ovarian cancer tissues using SEC31A mouse mAb with DAB staining.| Application Notes | WB:1:250~1:1000 IHC:1:20~1:100 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Purified antibody in PBS with 0.05% sodium azide |
|---|---|
| Storage Instructions | 4℃; -20℃ for long term storage |
